See more : Diageo plc (DGE.L) Income Statement Analysis – Financial Results
Complete financial analysis of Amrutanjan Health Care Limited (AMRUTANJAN.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amrutanjan Health Care Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- gooddays holdings, Inc. (4437.T) Income Statement Analysis – Financial Results
- Fractyl Health, Inc. Common Stock (GUTS) Income Statement Analysis – Financial Results
- Prince Housing & Development Corp. (2511.TW) Income Statement Analysis – Financial Results
- MBK Co.,Ltd. (3121.T) Income Statement Analysis – Financial Results
- PolyPid Ltd. (PYPD) Income Statement Analysis – Financial Results
Amrutanjan Health Care Limited (AMRUTANJAN.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrutanjan.com
About Amrutanjan Health Care Limited
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms, non-alcoholic beverages, and sanitary napkins. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons and lotions, body pain gels, and joint muscle sprays, as well as diclofenac, a non-steroidal anti-inflammatory drug. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, South East Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.21B | 3.80B | 4.05B | 3.32B | 2.61B | 2.52B | 2.22B | 2.22B | 1.87B | 1.67B | 1.42B | 1.37B | 1.43B | 1.05B | 897.70M | 906.60M | 745.49M | 723.88M |
| Cost of Revenue | 2.12B | 1.82B | 1.80B | 1.40B | 1.17B | 1.19B | 967.74M | 859.96M | 670.35M | 627.54M | 570.05M | 601.53M | 648.15M | 432.55M | 319.41M | 369.55M | 293.28M | 267.72M |
| Gross Profit | 2.09B | 1.98B | 2.25B | 1.91B | 1.44B | 1.33B | 1.25B | 1.36B | 1.20B | 1.04B | 847.23M | 765.04M | 783.33M | 621.48M | 578.28M | 537.06M | 452.21M | 456.15M |
| Gross Profit Ratio | 49.71% | 52.05% | 55.49% | 57.72% | 55.10% | 52.81% | 56.41% | 61.27% | 64.10% | 62.33% | 59.78% | 55.98% | 54.72% | 58.96% | 64.42% | 59.24% | 60.66% | 63.02% |
| Research & Development | 0.00 | 11.95M | 11.28M | 8.71M | 10.50M | 10.58M | 9.76M | 9.30M | 4.34M | 1.17M | 1.01M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 262.68M | 44.61M | 27.27M | 24.36M | 24.41M | 24.41M | 31.17M | 13.88M | 7.96M | 265.73M | 33.76M | 35.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 734.90M | 525.82M | 729.36M | 555.94M | 515.03M | 493.78M | 437.83M | 376.35M | 299.27M | 202.51M | 199.03M | 167.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 786.90M | 525.82M | 756.64M | 580.30M | 539.44M | 518.19M | 469.00M | 390.23M | 307.23M | 468.24M | 508.05M | 167.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.30B | 145.42M | 667.00K | 14.42M | 1.31M | 1.21M | 17.00K | 693.59M | 13.20K | 13.20K | 13.20K | 418.07M | 31.24M | 462.11M | 344.63K | 1.53M | 7.47M | 5.41M |
| Operating Expenses | 2.08B | 1.58B | 1.45B | 1.19B | 1.17B | 1.04B | 985.00M | 1.09B | 914.23M | 823.83M | 656.81M | 585.50M | 590.88M | 462.11M | 409.39M | 356.36M | 357.38M | 307.39M |
| Cost & Expenses | 3.75B | 3.40B | 3.26B | 2.60B | 2.34B | 2.22B | 1.95B | 1.95B | 1.58B | 1.45B | 1.23B | 1.19B | 1.24B | 894.66M | 728.81M | 725.90M | 650.67M | 575.11M |
| Interest Income | 148.05M | 117.06M | 111.70M | 93.88M | 65.72M | 54.06M | 44.99M | 33.68M | 33.13M | 26.69M | 6.91M | 7.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.51M | 771.00K | 4.85M | 5.00M | 2.21M | 822.00K | 1.27M | 4.32M | 3.14M | 6.93M | 17.66M | 24.79M | 31.24M | 3.37M | 344.63K | 1.53M | 7.47M | 5.41M |
| Depreciation & Amortization | 60.57M | 52.12M | 37.95M | 36.70M | 43.59M | 31.60M | 29.06M | 20.48M | 33.57M | 32.20M | 37.30M | 38.78M | 37.12M | 19.70M | 13.51M | 15.49M | 20.92M | 15.21M |
| EBITDA | 681.60M | 590.80M | 946.99M | 861.66M | 391.53M | 385.30M | 361.73M | 373.99M | 357.95M | 280.63M | 236.79M | 187.96M | 229.74M | 179.16M | 201.19M | 192.74M | 112.89M | 162.00M |
| EBITDA Ratio | 16.18% | 15.53% | 23.43% | 26.04% | 14.56% | 15.17% | 15.40% | 15.08% | 19.17% | 16.94% | 16.71% | 15.98% | 16.04% | 16.99% | 20.32% | 21.64% | 15.53% | 22.65% |
| Operating Income | 621.03M | 418.55M | 798.41M | 717.93M | 267.76M | 293.51M | 267.52M | 331.35M | 326.83M | 243.19M | 193.80M | 154.74M | 192.44M | 159.38M | 168.89M | 180.70M | 94.83M | 148.77M |
| Operating Income Ratio | 14.74% | 11.03% | 19.69% | 21.65% | 10.27% | 11.65% | 12.05% | 14.92% | 17.50% | 14.60% | 13.67% | 11.32% | 13.44% | 15.12% | 18.81% | 19.93% | 12.72% | 20.55% |
| Total Other Income/Expenses | -1.57M | 117.90M | 107.36M | 101.12M | 75.60M | 56.39M | 62.03M | 34.21M | -18.79M | 0.00 | 0.00 | 0.00 | -34.54M | -3.37M | 18.45M | -1.97M | -7.81M | -5.99M |
| Income Before Tax | 619.46M | 536.45M | 905.77M | 819.05M | 344.54M | 351.67M | 329.56M | 331.35M | 326.83M | 243.19M | 193.80M | 154.74M | 157.91M | 156.01M | 187.34M | 178.73M | 87.02M | 142.78M |
| Income Before Tax Ratio | 14.71% | 14.13% | 22.34% | 24.70% | 13.22% | 13.96% | 14.84% | 14.92% | 17.50% | 14.60% | 13.67% | 11.32% | 11.03% | 14.80% | 20.87% | 19.71% | 11.67% | 19.72% |
| Income Tax Expense | 169.73M | 138.11M | 233.88M | 207.14M | 93.71M | 101.70M | 129.06M | 117.26M | 121.08M | 92.45M | 69.37M | 53.57M | 61.56M | 53.89M | 72.62M | -745.21M | 36.75M | 83.65M |
| Net Income | 449.73M | 398.35M | 671.89M | 611.90M | 250.83M | 245.14M | 199.73M | 214.09M | 205.76M | 150.74M | 124.44M | 101.17M | 96.35M | 102.12M | 114.72M | 923.94M | 50.27M | 59.13M |
| Net Income Ratio | 10.68% | 10.50% | 16.57% | 18.46% | 9.62% | 9.73% | 9.00% | 9.64% | 11.02% | 9.05% | 8.78% | 7.40% | 6.73% | 9.69% | 12.78% | 101.91% | 6.74% | 8.17% |
| EPS | 15.50 | 13.65 | 23.00 | 20.94 | 8.58 | 8.39 | 6.83 | 7.46 | 7.67 | 5.10 | 4.26 | 3.46 | 16.23 | 3.37 | 3.78 | 29.05 | 1.57 | 1.85 |
| EPS Diluted | 15.41 | 13.63 | 22.98 | 20.93 | 8.58 | 8.39 | 6.83 | 7.46 | 7.67 | 5.10 | 4.26 | 3.46 | 16.23 | 3.37 | 3.78 | 29.05 | 1.57 | 1.85 |
| Weighted Avg Shares Out | 29.01M | 29.18M | 29.21M | 29.22M | 29.23M | 29.23M | 29.23M | 29.22M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 30.30M | 30.36M | 31.80M | 32.00M | 32.00M |
| Weighted Avg Shares Out (Dil) | 29.18M | 29.23M | 29.24M | 29.24M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 29.23M | 30.30M | 30.36M | 31.80M | 32.00M | 32.00M |
Source: https://incomestatements.info
Category: Stock Reports